CD46 and Miyoshi myopathy: If CD46 is highly expressed on 1q+ MM-ICs, and CD46–ADC can be demonstrated to eliminate disease with a patient-relevant approach, there would be sound rationale to design a clinical trial in the remission setting in attempt to achieve cure.